Cardiology
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology
Genetics
Geriatrics/Aging
Hematology/Oncology
Immunology/Allergy
Infectious Disease
Nephrology
Neurology/Neurosurgery
Obstetrics/Gynecology
Pediatrics
Psychiatry
Public Health, Policy, and Training
Pulmonary
Rheumatology
Surgery

Nejm News Une Mise à Jour The New England Journal of Medicine by Specialties

 


The New England Journal of Medicine: Search Results in Allergy\Immunology
The New England Journal of Medicine (NEJM) RSS feed -- Search Results in Allergy\Immunology. NEJM (http://www.nejm.org) is a weekly general medical journal that publishes new medical research findings, review articles, and editorial opinion on a wide variety of topics of importance to biomedical science and clinical practice.

Oral Glucocorticoid?Sparing Effect of Benralizumab in Severe Asthma
31/12/69 - Asthma is a common chronic inflammatory disease of the airways that affects an estimated 315 million persons worldwide. Approximately 5 to 10% of persons with asthma have a severe form of disease that is usually managed with high-dose inhaled glucocorticoids and bronchodilators. Within this group,…

Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis
31/12/69 - Eosinophilic granulomatosis with polyangiitis (formerly known as the Churg?Strauss syndrome) is characterized by asthma, sinusitis, pulmonary infiltrates, neuropathy, and eosinophilic vasculitis of one or more end-organs. Eosinophils are thought to induce pathogenic effects in patients with…

KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma
31/12/69 - Many patients with severe asthma do not have adequate disease control despite the use of high-dose inhaled or systemic glucocorticoids. Severe asthma is associated with airway hyperresponsiveness ? that is, an exaggerated response to a bronchoconstrictor stimulus ? and airway inflammation, both of…

Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade
31/12/69 - To the Editor: Patients with autoimmune diseases have typically been excluded from immunotherapy clinical trials, although recent evidence suggests that the benefits of checkpoint therapy may outweigh the risks of autoimmune flare-ups in carefully selected patients who have a high probability of…

Targeting Eosinophils in Eosinophilic Granulomatosis with Polyangiitis
31/12/69 - Eosinophilic granulomatosis with polyangiitis, first described in the early 1950s by Dr. Jacob Churg and Dr. Lotte Strauss (hence the original name, the Churg?Strauss syndrome), is a rare condition that can affect many organ systems, most commonly the lung, with the majority of patients presenting…

Mast Cells and KIT as Potential Therapeutic Targets in Severe Asthma
31/12/69 - Mast cells and many of their secreted products have long been thought to contribute to the pathologic processes underlying asthma, but no clinical studies have assessed whether specifically targeting mast-cell survival or development would have therapeutic benefit in the treatment of this disorder.…

Teprotumumab for Thyroid-Associated Ophthalmopathy
31/12/69 - Medical therapies for moderate-to-severe thyroid-associated ophthalmopathy (Graves? orbitopathy) that have proved to be effective and safe in adequately powered, prospective, placebo-controlled trials are lacking. This unmet need is due to the incompletely understood pathogenesis of the disease.…

Overexpression of the Cytokine BAFF and Autoimmunity Risk
31/12/69 - Multiple sclerosis and systemic lupus erythematosus (SLE) are autoimmune diseases caused by largely unknown environmental factors acting in genetically susceptible persons. Genomewide association studies have provided statistical support for more than 110 independent signals for multiple sclerosis…

A BAFFling Association between Malaria Resistance and the Risk of Multiple Sclerosis
31/12/69 - B cells are increasingly recognized as a therapeutic target in autoimmune diseases. B-cell?depleting therapy with the use of rituximab, a monoclonal antibody to CD20, is approved for the treatment of rheumatoid arthritis and antineutrophil cytoplasmic antibody?associated vasculitis and is…

Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia
31/12/69 - In patients with aplastic anemia, the "empty" bone marrow does not produce blood cells, and when pancytopenia is severe and untreated, almost all patients die within 1 year after diagnosis. Acquired aplastic anemia has immune pathophysiological features, as inferred from numerous laboratory studies…

Copyright © 2004/2011 Health.Cat

Annuaire de Sante | S'inscrire au MedSante  | Dictionnaire medicale  Forumed des médecins